news aktuell GmbH

Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal

Share
Janneke van der Kamp has today assumed her role as the new Chief Commercial Officer (CCO) of Grünenthal. She joins Grünenthal’s executive board and is responsible for the entire Global Commercial Organisation
Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal
Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal

(Aachen, Germany): As CCO of Grünenthal, Janneke van der Kamp’s focus will be to further strengthen Grünenthal’s commercial activities and grow the company’s key brands, especially Qutenza® (8% capsaicin topical system) in the US. Janneke van der Kamp will also be responsible for the launch preparations of Grünenthal’s promising pipeline asset, resiniferatoxin (RTX), for treating patients with moderate to severe pain associated with knee osteoarthritis. An ongoing clinical Phase III programme across sites in Europe, the US, Latin America, South Africa, and Japan aims to enable marketing approval for the investigational medicine.

Janneke van der Kamp joins Grünenthal at an exciting point in the company’s transformation journey. Since 2017, Grünenthal’s profitability, measured by adjusted EBITDA, has more than tripled. During this time, Grünenthal closed successful acquisitions with a total expected deal value of more than € 2 billion. Furthermore, the company expanded its geographical footprint, with its affiliate Averitas Pharma, Inc., commercialising Qutenza® (8% capsaicin topical system) in the US.

“I am thrilled to join Grünenthal at such an exciting time and work with colleagues across the world on our vision of a world free of pain,” says Janneke van der Kamp. “I am confident that together we will reach even more patients with our medicines and be optimally prepared for the launch of our late pipeline assets.”

Janneke van der Kamp joins Grünenthal from Novartis, where she most recently served as Head of Pharma Region Europe. The Dutch native brings broad experience in the pharmaceutical industry from several roles, including General Manager, Global Neurosciences Franchise Head, and Global Head of Product and Portfolio Strategy for the entire Novartis Pharma portfolio. She has vast expertise in launching and growing key brands across several disease areas. Janneke van der Kamp is a studied chemist and holds an MBA from INSEAD.

Janneke van der Kamp succeeds Mark Fladrich, who will retire from Grünenthal after more than five years with the company. During this time, he transformed Grünenthal’s commercial organisation, contributing to the company’s strong profit growth throughout his tenure.

Janneke van der Kamp’s Bio can be read here:
Leadership at Grünenthal | About us | Grünenthal (grunenthal.com)

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.

More information: www.grunenthal.com

Click here for our Grünenthal Report 2021/2022

Images

Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal
Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal
Download

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories20.3.2023 09:43:28 CET | Press release

Acquisition strengthens Adragos end-to-end integrated service offering within the pharmaceutical product development segment Agreement includes further product development activities for Clinigen Limited Lamda spurs further growth for Adragos as its 3rd site in Europe, and 5th globally (Munich / London / Athens) – Munich-based pharmaceutical contract development organization (CDMO) Adragos Pharma GmbH has signed a definitive agreement with global pharmaceutical services company Clinigen Limitedto acquire Lamda Laboratories S.A. in Athens. The acquisition of Lamda Laboratories significantly expands Adragos' pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers. Lamda has not only acted as Clinigen’s sole development center but has also established a well-earned reputation as a highly reliable contract development organization (CDO) for third party customers. Under a pharmaceutical development services agreemen

NP-Invest GmbH: Extreme swimmer braves the forces of nature / Nathalie Pohl is the first German woman to cross New Zealand’s Cook Strait2.3.2023 10:30:18 CET | Pressemelding

- Picture is available at AP Images (http://www.apimages.com) – (Marburg, Germany): It seems as if neither a cyclone nor an earthquake can stop her and her ambition is limitless: In her third attempt, extreme swimmer Nathalie Pohl has successfully managed to cross New Zealand’s Cook Strait as the first German woman and the fastest European woman to do so. With an exceptional time of 06:33:00 hours, the 28-year-old reached the finish line on Ohau Bay at 4.30 p. m. local time (UTC+13) on 1 March. A very hazardous channel The passage between Ohau Bay on New Zealand’s North Island and Arapawa Island on its South Island is considered particularly dangerous. Only 130 extreme swimmers worldwide have ever successfully made the crossing. In addition to being a busy shipping lane, there are often sharks to contend with and significant seismic shifts on the seabed, which can cause dangerous currents. The Cook Strait is also known for its rough seas. Strong currents can add many hours to the swim.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom